BidaskClub upgraded shares of Retrophin, Inc. (NASDAQ:RTRX) from a buy rating to a strong-buy rating in a research note published on Thursday.

Several other analysts have also issued reports on RTRX. TheStreet raised shares of Retrophin from a d rating to a c- rating in a research report on Friday, May 12th. Zacks Investment Research cut shares of Retrophin from a strong-buy rating to a hold rating in a research note on Wednesday, May 3rd. Finally, ValuEngine raised shares of Retrophin from a sell rating to a hold rating in a research note on Monday, July 17th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $32.25.

Retrophin (NASDAQ RTRX) opened at 23.72 on Thursday. The firm’s market capitalization is $910.49 million. The firm’s 50-day moving average is $20.97 and its 200 day moving average is $19.32. Retrophin has a 52-week low of $15.55 and a 52-week high of $24.57.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.10. The company had revenue of $38.80 million during the quarter, compared to the consensus estimate of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business’s revenue was up 16.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 EPS. Equities analysts anticipate that Retrophin will post ($1.13) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/28/retrophin-inc-rtrx-rating-increased-to-strong-buy-at-bidaskclub.html.

In related news, COO Neil F. Mcfarlane sold 1,378 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total transaction of $31,005.00. Following the sale, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at approximately $306,495. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.41% of the company’s stock.

Several institutional investors have recently modified their holdings of RTRX. SG Americas Securities LLC boosted its position in shares of Retrophin by 1.8% in the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the period. Legal & General Group Plc boosted its stake in Retrophin by 4.3% in the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 355 shares during the last quarter. Weiss Multi Strategy Advisers LLC purchased a new stake in Retrophin during the first quarter worth approximately $185,000. Dynamic Technology Lab Private Ltd purchased a new stake in Retrophin during the first quarter worth approximately $219,000. Finally, Fox Run Management L.L.C. purchased a new stake in Retrophin during the second quarter worth approximately $246,000.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.